1 江苏鱼跃医疗设备股份有限公司 目录 CONTENTS 优质医疗可及 降低环境影响 91 2 3 35 41 53 01 董事长致辞 03 关于鱼跃医疗 05 可持续发展管理 11 行稳致远 迈向高质量发展新征程 强化公司治理 恪守商业道德 信息安全与隐私保护 可持续供应链 13 19 23 27 59 以人为本 成就生命价值 人力资本发展 员工权益保障 守护生命健康 61 74 77 33 创新引领 让科技律动生命 创新赋能健康 坚守品质初心 81 环境友好 共赢绿色未来 加强环境管理 应对气候变化 83 85 97 关键绩效表 101 报告编制说明 102 指标索引 江苏鱼跃医疗设备股份有限公司 董事长致辞 责任与担当贯穿鱼跃医疗的奋进历程。多年来，我们 心怀热爱、砥砺前行，以科技创新注入新动能，以质 效提升推动新增长，努力成为创新转型的引领者和人 民健康的守护者。2024 年，健康管理需求持续增长， 产业变革加速推进，在不断变化的全球环境中，我们 始终怀抱着"通过创新引领行业发展，提升千万家庭 健康水平"的愿景，以健康立心，以科技立行，主动 融入和服务国家战略，积极拥抱变革和机遇，立足长 期主义探索可 ...

| 关联 | | 关联交 | 预计金额 | 年初至披露日 | 上年实际发生 | | | --- | --- | --- | --- | --- | --- | --- | | 交易 | 关联人 | | | 已发生金额 | 发生金额 | 占同类业 | | | | 易内容 | （万元） | | | 务比例 | | 类别 | | | | （万元） | （万元） | | | | | | | | | （%） | | 向关联 | | 采购货物 | | | | | | 人采购 | 苏州日精 | | 4,000.00 | 587.69 | 3,120.46 | 0.86 | | 货物/接 | | 接受劳务 | | | | | | 受劳务 | | | | | | | | | 小计 | - | 4,000.00 | 587.69 | 3,120.46 | - | 证券代码：002223 证券简称：鱼跃医疗 公告编号：2025-015 江苏鱼跃医疗设备股份有限公司 关于 2025 年度日常关联交易预计的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、日常关联交易的基本情况 ...

证券代码：002223 证券简称：鱼跃医疗 公告编号：2025-018 江苏鱼跃医疗设备股份有限公司 关于召开 2024 年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 经江苏鱼跃医疗设备股份有限公司（以下简称"鱼跃医疗"或"公司"）第 六届董事会第四次会议提请，公司将于2025年5月16日召开2024年度股东大会， 现就本次股东大会相关事项通知如下： 一、召开会议的基本情况 （一）股东大会届次：2024年度股东大会； （二）会议的召集人：公司董事会； （三）会议召开的合法、合规性：本次股东大会的召开符合《中华人民共和 国公司法》《上市公司股东会规则》等法律、法规、规范性文件及《江苏鱼跃医 疗设备股份有限公司章程》的有关规定。 （四）会议召开时间： 1、现场会议时间：2025年5月16日下午13:30 2、网络投票时间：2025年5月16日 通过深圳证券交易所交易系统进行网络投票的时间为2025年5月16日 9:15~9:25，9:30~11:30，13:00~15:00； 通过深圳证券交易所互联网投票系统投票的时间为2025年5月16日上 ...

证券代码：002223 证券简称：鱼跃医疗 公告编号：2025-012 2025 年 4 月 25 日，江苏鱼跃医疗设备股份有限公司（以下简称"公司"） 以通讯表决的方式召开了第六届监事会第四次会议。公司于 2025 年 4 月 16 日以 书面送达及电子邮件形式向公司全体监事发出了召开公司第六届监事会第四次 会议的通知，经全体监事一致同意，豁免本次监事会的通知时限。会议应到监事 7 人，实到监事 7 人。本次会议的召集、召开符合《中华人民共和国公司法》和 《公司章程》的有关规定，会议决议合法、有效。会议由公司监事会主席吕英芳 先生主持，经与会监事充分讨论，审议通过了如下议案： 二、监事会会议审议情况 1、关于《公司2024年度监事会工作报告》的议案 表决结果：同意：7票；反对：0票；弃权：0票 江苏鱼跃医疗设备股份有限公司 第六届监事会第四次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 《江苏鱼跃医疗设备股份有限公司2024年度监事会工作报告》详见2025年4 月26日巨潮资讯网（www.cninfo.com.cn）。 ...

证券代码：002223 证券简称：鱼跃医疗 公告编号：2025-011 江苏鱼跃医疗设备股份有限公司 二、董事会会议审议情况 1、关于《公司 2024 年度总经理工作报告》的议案 表决结果：同意：9 票；反对：0 票；弃权：0 票 2、关于《公司 2024 年度董事会工作报告》的议案 表决结果：同意：9 票；反对：0 票；弃权：0 票 《江苏鱼跃医疗设备股份有限公司 2024 年度董事会工作报告》内容具体详 见《2024 年年度报告》第三节《管理层讨论与分析》部分及第四节《公司治理》 部分。 第六届董事会第四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 2025 年 4 月 25 日，江苏鱼跃医疗设备股份有限公司（以下简称"公司"） 以通讯表决的方式召开了第六届董事会第四次会议。公司于 2025 年 4 月 16 日以 书面送达及电子邮件方式发出了召开公司第六届董事会第四次会议的通知以及 提交审议的议案，经全体董事一致同意，豁免本次董事会的通知时限。会议应出 席董事 9 名，实际出席会议董事 9 名。本次会议的召集、召 ...

Financial Performance - The company's operating revenue for 2024 was ¥7,565,819,017.28, a decrease of 5.09% compared to ¥7,971,734,452.47 in 2023[19]. - Net profit attributable to shareholders for 2024 was ¥1,805,700,655.26, reflecting a decline of 24.63% from ¥2,395,853,276.49 in 2023[19]. - The net cash flow from operating activities decreased by 14.61% to ¥1,816,269,732.77 in 2024, down from ¥2,126,977,841.98 in 2023[19]. - Basic earnings per share for 2024 were ¥1.81, a drop of 24.90% compared to ¥2.41 in 2023[19]. - Total assets at the end of 2024 were ¥15,645,782,499.04, down 2.01% from ¥15,967,458,083.34 at the end of 2023[20]. - The net assets attributable to shareholders increased by 6.56% to ¥12,535,332,607.69 in 2024, compared to ¥11,763,562,138.83 in 2023[20]. - The company reported a significant decrease in non-recurring gains, with a total of ¥412,861,542.07 in 2024 compared to ¥560,231,652.24 in 2023[28]. - The company achieved total revenue of 7.566 billion yuan, a year-on-year decrease of 5.09%[47]. - Operating profit was 1.932 billion yuan, down 33.24% year-on-year[47]. - The company has a total asset of 15.646 billion yuan and a debt-to-asset ratio of 19.12%[48]. - The company's cash flow from operating activities was 1.816 billion yuan, a decrease of 14.61% year-on-year[48]. Dividend Distribution - The company plans to distribute a cash dividend of 4.00 yuan per 10 shares (including tax) to all shareholders[4]. - The company distributed a cash dividend of CNY 8.00 per 10 shares (including tax) totaling CNY 802 million for the 2023 annual profit distribution, and plans to distribute CNY 4.00 per 10 shares (including tax) totaling CNY 401 million for the 2024 interim dividend[112]. - The cumulative cash dividend for 2024 is expected to reach CNY 802 million, accounting for 44.40% of the net profit attributable to shareholders of the listed company[112]. Market and Industry Insights - The global medical device market size reached $582.6 billion in 2023, with a compound annual growth rate (CAGR) of approximately 6.37% from 2018 to 2023, and is expected to grow further in 2024[30]. - China's medical device market size reached 1,032.8 billion RMB in 2023, with a CAGR of 16.12% from 2016 to 2023, making it the second-largest market globally[30]. - The medical device industry in China is experiencing consolidation and increased R&D investment, with a focus on smart and diversified products driven by technological advancements[32]. - The Chinese medical device industry is transitioning from rapid growth to high-quality development, driven by policy support, demographic changes, and increased health awareness[92]. - The home medical device market is expanding due to the aging population and rising health management needs, leading to increased demand for home health monitoring and rehabilitation equipment[90]. Product Development and Innovation - The company focuses on home medical devices, clinical products, and related services, with core business areas including respiratory therapy, blood glucose management, and home health monitoring[34]. - The company has established a comprehensive technology and product system in diabetes management, recently launching the new "Anytime" continuous glucose monitoring series[37]. - The company is leveraging its scale, intelligence, and lean production capabilities to enhance its competitive edge in the diabetes management sector[37]. - The company has launched several new products, including advanced endoscope cleaning products and new generation AEDs, to enhance market competitiveness[68]. - The company is currently developing new high-flow humidification therapy devices and advanced non-invasive ventilators, which are in clinical trials[63]. - The company is expanding its product line with new continuous glucose monitoring (CGM) systems, enhancing market competitiveness and aiming for overseas sales[67]. Research and Development - R&D expenses amounted to 547 million yuan, a year-over-year increase of 8.39%, indicating the company's commitment to innovation and technology enhancement[54]. - The company has increased its R&D personnel by 18.23% from 1,031 in 2023 to 1,219 in 2024, with a corresponding increase in the proportion of R&D personnel from 16.86% to 19.21%[70]. - R&D investment has risen by 8.39% from approximately ¥504.37 million in 2023 to ¥546.68 million in 2024, with R&D investment as a percentage of operating revenue increasing from 6.33% to 7.23%[70]. Corporate Governance and Management - The company emphasizes investor relations management and has received an "A" rating in the 2023-2024 information disclosure assessment by the Shenzhen Stock Exchange[111]. - The company has established independent financial and operational systems, ensuring compliance with relevant laws and regulations[114][122]. - The board of directors has held multiple meetings to review and approve the company's quarterly reports, ensuring transparency and accountability[145]. - The company has implemented a performance evaluation system for its directors and senior management, determining their annual salary based on company performance and individual achievements[143]. - The company has maintained a stable shareholding structure with no significant increases or decreases reported[124]. Social Responsibility and Sustainability - The company actively engages in social responsibility, focusing on protecting the rights of shareholders, creditors, employees, suppliers, customers, and consumers, while also promoting environmental protection and sustainable development[178]. - The company has implemented various measures to reduce carbon emissions, including the establishment of a smart central energy system and water resource management system, which have improved production efficiency and reduced energy consumption[176]. - During the reporting period, the company donated essential medical equipment to grassroots health institutions in the southwest region as part of its targeted poverty alleviation projects[179]. Risk Management - The company emphasizes the importance of risk awareness regarding future plans and performance forecasts, indicating potential industry challenges[4]. - The company will implement a risk management system to mitigate potential risks and ensure stable and sustainable growth[96].

Financial Performance - The company's revenue for Q1 2025 was ¥2,435,873,177.34, representing a 9.17% increase compared to ¥2,231,209,294.86 in the same period last year[5] - Net profit attributable to shareholders decreased by 5.26% to ¥624,758,641.94 from ¥659,412,768.43 year-on-year[5] - The net cash flow from operating activities was ¥657,714,515.09, down 2.64% from ¥675,553,263.28 in the previous year[5] - Total operating revenue for the current period reached ¥2,435,873,177.34, an increase of 9.2% compared to ¥2,231,209,294.86 in the previous period[30] - Net profit for the current period was ¥623,182,616.76, a decrease of 5.7% from ¥661,025,126.81 in the previous period[32] - Basic and diluted earnings per share were both ¥0.6271, down from ¥0.6619 in the prior period[32] - The company reported a total profit of ¥737,099,415.22, down from ¥778,193,564.96 in the previous period, reflecting a decline in overall profitability[32] Assets and Liabilities - Total assets increased by 4.93% to ¥16,416,376,751.82 from ¥15,645,782,499.04 at the end of the previous year[5] - The company's total liabilities as of March 31, 2025, were CNY 3,189,273,124.05, with current liabilities totaling CNY 2,900,863,483.46[28] - The company's total equity as of March 31, 2025, was CNY 13,227,103,627.77, reflecting a strong financial position[28] - Cash and cash equivalents increased to CNY 7,079,594,847.56 from CNY 6,618,648,637.69, indicating improved liquidity[26] Cash Flow - The net cash flow from investing activities decreased by 589.34%, mainly due to strategic investments in directed share placements[9] - The company experienced a 97.64% increase in net cash flow from financing activities, primarily due to last year's loan repayments[9] - Cash flow from operating activities generated a net amount of ¥657,714,515.09, slightly down from ¥675,553,263.28 in the previous period[34] - The company received cash inflows from operating activities totaling ¥2,358,650,181.12, an increase from ¥2,281,354,434.16 in the previous period[34] Shareholder Information - The total number of common stock shareholders at the end of the reporting period is 49,184[11] - Jiangsu Yuyue Technology Development Co., Ltd. holds 24.54% of shares, totaling 245,983,450 shares[11] - The top ten shareholders collectively hold significant stakes, with the largest shareholder owning 24.54%[11] - As of February 26, 2025, the employee stock ownership plan holds 6,010,616 shares, accounting for 0.60% of the company's total share capital[21] Investments and Partnerships - The company has invested up to RMB 60 million in the Nanjing Shengyu Heike New Intelligent Manufacturing Venture Capital Partnership[14] - The company subscribed to 2,626,425 shares of Inogen, representing 9.9% of Inogen's issued common stock after the investment[16] - The company has established a strategic cooperation agreement with Inogen for international distribution, trademark licensing, joint R&D, and supply chain optimization[16] - The company has completed the capital contribution to the partnership and will not need to make further contributions[14] Product Development and Innovation - The company received a medical device registration certificate for its 15-day calibration-free/calibrated dual-mode continuous glucose monitoring system[18] - The company aims to enhance product offerings in diabetes care solutions, focusing on accuracy, comfort, convenience, and digital management[18] - The company received the medical device registration certificate for the Continuous Glucose Monitoring System (CGM), which has a maximum usage time of 16 days and does not require user calibration, enhancing user experience and expanding the product matrix in blood glucose management[19] - The company’s automatic external defibrillator (AED) has obtained EU MDR certification, enhancing its competitiveness in the emergency medical field and facilitating business development in EU countries[23] - Research and development expenses increased to ¥156,329,663.86, up 25.6% from ¥124,450,232.82 in the prior period, indicating a focus on innovation[31] Operational Costs - Total operating costs amounted to ¥1,816,105,564.51, up 14.6% from ¥1,584,225,003.71 in the prior period, with operating costs specifically rising to ¥1,210,554,322.86, a 8.4% increase from ¥1,116,936,863.37[31] - Sales expenses rose by 32.67%, primarily due to increases in salaries, bonuses, and advertising costs[8] Other Financial Information - Other comprehensive income after tax showed a net loss of ¥53,795,499.78, compared to a loss of ¥2,952,891.55 in the previous period[32] - The first quarter report has not been audited[36] - The new accounting standards will be implemented starting in 2025[36] - The financial statement items related to the first year of implementation will be adjusted accordingly[36] - The board of directors of Jiangsu Yuyue Medical Equipment Co., Ltd. issued the report on April 26, 2025[36]

江苏鱼跃医疗设备股份有限公司的主营业务是研发、制造和销售医疗器械产品及提供相关解决方案。公 司产品主要集中在呼吸制氧、糖尿病护理、感染控制解决方案、家用类电子检测及体外诊断、急救与临 床及康复器械等业务领域。公司目前拥有"鱼跃yuwell"、"洁芙柔"、"华佗Hwato"、"金钟JZ"、"安尔 碘"、"普美康PRIMEDIC"、"六六视觉"等几大主要品牌。"鱼跃"品牌深入人心，依托鱼跃产品力的不断 提升及有效的品牌传播，以及旗下产品在海内外医疗一线的卓越表现，公司品牌价值和品牌优势显著提 升。 最新一期业绩显示，2024年三季报，公司实现营业收入60.28亿元，同比-9.53%；净利润15.32亿元，同 比-30.09%，销售毛利率50.13%。 4月25日，鱼跃医疗今日收盘33.21元，下跌3.26%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到19.17倍，总市值332.92亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)44鱼跃医疗19.1713.902.66332.92亿行业平均 45.1147.464.59101.63亿行业中值33.8331.852.2945.98亿1 ...

从指数持仓来看，中证全指医疗行业指数十大权重分别为：迈瑞医疗（14.15%）、爱尔眼科 （8.89%）、联影医疗（7.82%）、爱美客（4.05%）、惠泰医疗（4.0%）、鱼跃医疗（3.12%）、上海 医药（3.09%）、新产业（3.03%）、益丰药房（2.65%）、美年健康（2.5%）。 金融界4月22日消息，A股三大指数收盘涨跌不一，中证全指医疗行业指数 (医疗行业，932131)报537.08 点。 数据统计显示，中证全指医疗行业指数近一个月下跌5.24%，近三个月下跌0.28%，年至今下跌5.24%。 据了解，中证全指行业优选指数系列从中证全指行业中选取符合一定流动性与市值筛选条件的上市公司 作为指数样本，以反映各个行业内较具代表性与可投资性的上市公司证券的整体表现。该指数以2021年 12月31日为基日，以1000.0点为基点。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一个定期 调整日前，权重因子一般固定不变。遇临时调整时，当中证全指指数调整样本时，中证全指行业指数 ...